Analysis of public procurement of medicines for the treatment of patients with epilepsy
Keywords:clinical and economic analysis, public procurement, antiepileptic drugs, epilepsy
Aim. To analyze public procurement of medicines for the treatment of patients with epilepsy using methods of clinical and economic analysis.
Materials and methods. For the study, the official data of the Ministry of Health of Ukraine for 2014-2018 concerning public procurement of antiepileptic drugs were used. The total amount of public procurement of medicines for all trade names was determined, and the sums of purchases were grouped by international nonproprietary names. To conduct the analysis of public procurement of antiepileptic drugs, ABC and VEN analyses were performed. Based on the results of the integrated ABC / VEN analysis the volumes of procurement costs were ranked taking into account the requirements of the regulatory framework providing medical and pharmaceutical care for patients with epilepsy.
Results. According to the results of the study it was found that during 2014-2018 the average growth rate of public procurement of antiepileptic drugs in UAH equivalent was 136 %, and in dollar equivalent – 110 %. It was determined that in 2018 the volume of expenditures per patient for the purchase of antiepileptic drugs in UAH equivalent increased by 305 % compared to 2014. However, the volume of expenditures in terms of US dollars in 2018 increased only by 22 % compared to 2014. It is due to the fact that in 2014 there were crisis processes at the financial market of Ukraine, which led to an increase in the price of medicines and had a direct impact on the volume of expenses for the purchase of medicines. It has been proven that during 2014-2018 in the volume of public procurement there is a negative trend of prevalence of antiepileptic drugs of foreign manufacture. Thus, the ratio of the volume of costs for the purchase of foreign drugs to domestic ones amounted to 87 % to 13 %, respectively. The analysis of public procurement by the lines of therapy determined that the main share of the expenses belonged to the first-line pharmacotherapy drugs. The ABC analysis showed that the total government spending on the purchase of antiepileptic drugs had uneven dynamics. The results of the VEN analysis indicated that any antiepileptic drugs for INN were not assigned to the category “N”. According to the results of the integrated ABC / VEN analysis it was found that the share of expenses from group A / V in the total amount of the antiepileptic drugs purchased ranged from 70.1 % (2014) to 72.8 % (2018).
Conclusions. The results of the study can be used in the development of scientific and applied approaches to the organization of effective financing of pharmaceutical care in Ukraine.
WHO Еpilepsy. (2019). Available at : https://www.who.int/ru/news-room/fact-sheets/detail/epilepsy (Date of Access: 01.05.2020).
WHO Еpilepsy. (2019). A public health imperative. Available at: http://www.who.int/mental_health/neurology/epilepsy/report_2019/en_171.pdf (Date of Access: 01.05.2020).
Volkova, A. V., Korzh, Yu. V, Oleinikova, N. V., Tereshchenko, L. V, Zaitseva, Yu. L. (2019). The study of the epileptic population morbidity rate in Ukraine at the state and regional level. Sotsialna farmatsiia v okhoroni zdorovia, 5 (4), 14-22. doi: 10.24959/sphhcj.19.173.
Rossyiskoe obshchestvo psykhyatrov. (2014). Diahnostika i lechenie psikhicheskikh rasstroistv pri epilepsii. Klinicheskie rekomendatsii. Moscow, 5-7. Available at: https://mzur.ru/upload.Эпилепсия.pdf (Date of Access: 01.05.2020).
Horachuk, V. V. (2011). Ukrainskyi medychnyi chasopys, 5 (85). Available at: https://www.umj.com.ua/article/18382/mediko-socialni-ta-ekonomichni-aspekti-epilepsii (Date of Access: 01.05.2020).
Kotvitska, A. A., Kononenko, O. V. (2015). Farmatsevtychnyi zhurnal, 6, 3–9.
Kotvitska, A. A., Krasulia, O. I., Kubarieva, I. V. (2012). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 6, 70–75.
Iakovlieva, L. V., Herasymova, O. O., Horbachova, A. S., Krasiuk, A. A. (2015). Farmatsevtychnyi chasopys, 3, 83–87.
Mnushko, Z. M., Sholoiko, N. V. (2008). Farmakoeoknomichni pidkhody do stvorennia optymalnoho pereliku likarskykh preparativ, neobkhidnykh dlia zakupivli za biudzhetni koshty (na prykladi hematolohichnoho viddilennia klinichnoi likarni). Kharkiv: NFaU, 19.
Nemchenko, A. S., Kosiachenko, K. L., Panfilova, H. L. (2011). Metodyka provedennia kliniko-ekonomichnoho analizu tendernykh zakupivel LZ za derzhavnymy tsilovymy prohramamy. Kharkiv: NFaU, 26.
Panfilova, H. L., Tsurikova, O. V. (2014). Zaporizkyi medychnyi zhurnal, 1 (82), 98–103.
Zakupivli likiv. Derzhavna informatsiia shchodo zakupivel za biudzhet. moz.gov.ua. Available at: https://moz.gov.ua/zakupivli-likiv (Date of Access: 01.05.2020).
Tsentr hromadskoho zdorovia MOZ Ukrainy. (2019). Zdorovia, shcho treba znaty pro epilepsiiu. Available at: https://phc.org.ua/news/scho-treba-znati-pro-epilepsiyu (Date of Access: 01.05.2020).
MOZ Ukrainy. (2014). Nakaz No. 276. 17.04.2014 “Unifikovanyi klinichnyi protokol pervynnoi, ekstrenoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy epilepsii u doroslykh”. mtd.dec.gov.ua. Available at: http://mtd.dec.gov.ua/images/dodatki/2014_276_Epilepsii/2014_276_YKPMD_epilepsiya_dorosli.pdf (Date of Access: 01.05.2020).
Postanova KMU vid 13.12.2017 No. 1081 “Pro vnesennia zmin do Natsionalnoho pereliku osnovnykh likarskykh zasobiv”. zakon.rada.gov.ua. Available at: https://zakon.rada.gov.ua/laws/show/1081-2017-%D0%BF#n8 (Date of Access: 01.05.2020).
Nakaz MOZ Ukrainy vid 06.05.2020 No. 1075 “Pro zatverdzhennia dvanadtsiatoho vypusku Derzhavnoho formuliara likarskykh zasobiv ta zabezpechennia yoho dostupnosti”. moz.gov.ua. Available at: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-06052020--1075-pro-zatverdzhennja-dvanadcjatogo-vipusku-derzhavnogo-formuljara-likarskih-zasobiv-ta-zabezpechennja-jogo-dostupnosti (Date of Access: 01.05.2020).
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).